Shuangshuang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shuangshuang Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gang Zhao
West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China
1 shared publication - Hao Sun
Department of Joint Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication Haohang Sun
Department of No.1 General Surgery, People's Hospital of Zhenhai, 315211, Ningbo, Zhejiang Province, China
1 shared publication- Hui Li
School of Chemical Engineering, Sichuan University, Chengdu 610065, China
1 shared publication Ji Dai
Department of General Surgery, Second Affiliated Hospital of Zhejiang University, 310058, Hangzhou, Zhejiang Province, China
1 shared publication- Li Li
Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
1 shared publication
Latest Publications
- Open Access
- 10 September 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (1) , 15-25
miR-539-5p Regulates Irritable Bowel Syndrome Pathological Processes by Targeting KDM6A
Background/Aims: The chronicity and recurrence of irritable bowel syndrome (IBS) pose significant burdens on patients’ lives, making it urgent to understand its underlying mechanisms. This study intends to investigate the function and regulatory mechanisms of miR 539-5p in IBS and lay the foundation for the creation of more effective therapeutic strategies. Materials and Methods: Rat model of IBS with diarrhea (IBS-D) was established and evaluated by the abdominal withdrawal reflex. The IBS cellular model was established in vitro using lipopolysaccharide (LPS), and real-time quantitative polymerase chain reaction was used to assess the changes in the miR-539-5p expression. Cell counting kit-8 assays, flow cytometry, and enzyme-linked immu nosorbent assay were used to evaluate the effects of different treatments on cell viability, paracellular permeability, apoptosis, and inflammatory responses. Bioinformatics techniques and dual-luciferase reporter gene assays were leveraged to forecast and confirm the interaction between miR-539-5p and the KDM6A gene. Results: In IBS-D rats, miR-539-5p was conspicuously downregulated, and miR-539-5p overexpression could improve the symptoms of rats. Under exposure to LPS, the expression of miR-539-5p was evidently decreased. Upregulating miR-539-5p could significantly mitigate LPS-induced cellular damage, namely inhibiting the apoptosis of intestinal mucosal epithelial cells, promoting cell prolifera tion, reducing paracellular permeability, and suppressing the inflammatory response. KDM6A, as the target gene of miR-539-5p, was remarkably upregulated in IBS-D rats and cells exposed to LPS. KDM6A overexpression counteracts the protective effects mediated by the upregulation of miR-539 5p. Conclusion: miR-539-5p may be involved in regulating the pathological processes of IBS-D by targeting KDM6A. Cite this article as: Li Y, Wang Z, Zhang S, Hua Y, Fan X, Li L. MiR-539-5p regulates irritable bowel syndrome pathological processes by targeting KDM6A. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24684.
- 10 September 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (1) , 15-25
Open AccessmiR-539-5p Regulates Irritable Bowel Syndrome Pathological Processes by Targeting KDM6A
Background/Aims: The chronicity and recurrence of irritable bowel syndrome (IBS) pose significant burdens on patients’ lives, making it urgent to understand its underlying mechanisms. This study intends to investigate the function and regulatory mechanisms of miR 539-5p in IBS and lay the foundation for the creation of more effective therapeutic strategies. Materials and Methods: Rat model of IBS with diarrhea (IBS-D) was established and evaluated by the abdominal withdrawal reflex. The IBS cellular model was established in vitro using lipopolysaccharide (LPS), and real-time quantitative polymerase chain reaction was used to assess the changes in the miR-539-5p expression. Cell counting kit-8 assays, flow cytometry, and enzyme-linked immu nosorbent assay were used to evaluate the effects of different treatments on cell viability, paracellular permeability, apoptosis, and inflammatory responses. Bioinformatics techniques and dual-luciferase reporter gene assays were leveraged to forecast and confirm the interaction between miR-539-5p and the KDM6A gene. Results: In IBS-D rats, miR-539-5p was conspicuously downregulated, and miR-539-5p overexpression could improve the symptoms of rats. Under exposure to LPS, the expression of miR-539-5p was evidently decreased. Upregulating miR-539-5p could significantly mitigate LPS-induced cellular damage, namely inhibiting the apoptosis of intestinal mucosal epithelial cells, promoting cell prolifera tion, reducing paracellular permeability, and suppressing the inflammatory response. KDM6A, as the target gene of miR-539-5p, was remarkably upregulated in IBS-D rats and cells exposed to LPS. KDM6A overexpression counteracts the protective effects mediated by the upregulation of miR-539 5p. Conclusion: miR-539-5p may be involved in regulating the pathological processes of IBS-D by targeting KDM6A. Cite this article as: Li Y, Wang Z, Zhang S, Hua Y, Fan X, Li L. MiR-539-5p regulates irritable bowel syndrome pathological processes by targeting KDM6A. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24684.
- 11 May 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 560, 119-125
LncRNA MAFG-AS1 affects the tumorigenesis of breast cancer cells via the miR-574-5p/SOD2 axis
- 11 May 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 560, 119-125
LncRNA MAFG-AS1 affects the tumorigenesis of breast cancer cells via the miR-574-5p/SOD2 axis
- 6 November 2015
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 82 (03) , 224-229
A Rapid, Selective and Sensitive UPLC-MS/MS Method for Quantification of Nomilin in Rat Plasma and Its Application in a Pharmacokinetic Study
Nomilin is a potential anticancer agent. In this study, a rapid, sensitive, and simple ultra-performance liquid chromatography with tandem mass spectrometry methodology was established and validated to quantify nomilin in rat plasma. Plasma samples were prepared through liquid-liquid extraction using ethyl acetate. Chromatographic separation was performed using an Acquity HSS T3 column. Acetonitrile and water containing 0.1 % (v/v) formic acid were used as mobile phases at a flow rate of 0.3 mL/min. Nomilin and quercetin (internal standard) were detected and quantified via a triple quadrupole tandem mass spectrometer in the positive ion mode with multiple reaction monitoring. Tandem mass spectrometry detection was performed by monitoring the fragmentations of m/z 515.3 → m/z 161.0 and m/z 303.2 → m/z 153.1 of nomilin and quercetin, respectively. Good linearity (R2 > 0.996) was observed in the concentration range of 1 ng/mL to 500 ng/mL with a lower limit of quantification of 1 ng/mL for nomilin. The average extraction recoveries of nomilin and quercetin were > 82.3 % and 82.0 %, respectively. Intra- and interday precisions were less than 15 % and accuracy ranged from 85.0 % to 90.1 %. Indeed, the proposed method was successfully applied to analyze the pharmacokinetics of nomilin after 3 and 50 mg/kg nomilin were administered to rats via intravenous and oral routes, respectively.
- 6 November 2015
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 82 (03) , 224-229
A Rapid, Selective and Sensitive UPLC-MS/MS Method for Quantification of Nomilin in Rat Plasma and Its Application in a Pharmacokinetic Study
Nomilin is a potential anticancer agent. In this study, a rapid, sensitive, and simple ultra-performance liquid chromatography with tandem mass spectrometry methodology was established and validated to quantify nomilin in rat plasma. Plasma samples were prepared through liquid-liquid extraction using ethyl acetate. Chromatographic separation was performed using an Acquity HSS T3 column. Acetonitrile and water containing 0.1 % (v/v) formic acid were used as mobile phases at a flow rate of 0.3 mL/min. Nomilin and quercetin (internal standard) were detected and quantified via a triple quadrupole tandem mass spectrometer in the positive ion mode with multiple reaction monitoring. Tandem mass spectrometry detection was performed by monitoring the fragmentations of m/z 515.3 → m/z 161.0 and m/z 303.2 → m/z 153.1 of nomilin and quercetin, respectively. Good linearity (R2 > 0.996) was observed in the concentration range of 1 ng/mL to 500 ng/mL with a lower limit of quantification of 1 ng/mL for nomilin. The average extraction recoveries of nomilin and quercetin were > 82.3 % and 82.0 %, respectively. Intra- and interday precisions were less than 15 % and accuracy ranged from 85.0 % to 90.1 %. Indeed, the proposed method was successfully applied to analyze the pharmacokinetics of nomilin after 3 and 50 mg/kg nomilin were administered to rats via intravenous and oral routes, respectively.